Sosana Bdir

Dr. Sosana Bdir


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

10 June 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
Mohammad QneibiMohammad Qneibi
Mohammad Qneibi
MHmohammed hawash
mohammed hawash
NJNidal Jaradat
Nidal Jaradat
Sosana BdirSosana Bdir
Sosana Bdir

15 August 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Mohammad QneibiMohammad Qneibi
Mohammad Qneibi
HJHanan Jumaa
Hanan Jumaa
Sosana BdirSosana Bdir
Sosana Bdir
NANawaf Al-Maharik
Nawaf Al-Maharik
Three major subtypes of ionotropic receptors regulate glutamatergic synaptic transmission, one of which is α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors (AMPARs). They are tetrameric, cation-permeable ionotropic glutamate receptors found across the brain. Abnormalities in AMPA receptor trafficking and synaptic assembly are linked to cognitive decline and neurological diseases such as Alzheimer’s, Parkinson’s, and Huntington’s. The present study will investigate the effects of four novel 2,3-benzodiazepine derivatives on AMPA receptor subunits by comparing their effects on synaptic responses, desensitization, and deactivation rate in human embryonic kidney cells (HEK293T) recombinant AMPAR subunits using whole-cell patch-clamp electrophysiology. All four 2,3-BDZ compounds showed inhibitory activity against all the homomeric and heteromeric subunits tested. While the desensitization and deactivation rates in 2,3-BDZ-1 and 2,3-BDZ-2 decreased and increased, respectively, in the other two compounds (i.e., 2,3-BDZ-3 and 2,3-BDZ-4), there was no change in the desensitization or deactivation rates. These results contribute to a better understanding of AMPARs by identifying potential 2,3-BDZ drugs that demonstrate inhibitory effects on the AMPAR subunits.

25 September 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Sosana BdirSosana Bdir
Sosana Bdir
MJMennatallah Maher Jaber
Mennatallah Maher Jaber
OTOsaid Tanbouz
Osaid Tanbouz
FMFathi Milhem
Fathi Milhem
ISIyas Sarhan
Iyas Sarhan
Mohammad QneibiMohammad Qneibi
Mohammad Qneibi
Background/Objectives: Acute myocardial infarction (MI) is a major cause of death worldwide, and it imposes a heavy burden on health care systems. Although diagnostic methods have improved, detecting the disease early and accurately is still difficult. Recently, AI has demonstrated increasing capability in improving ECG-based MI detection. From this perspective, this scoping review aimed to systematically map and evaluate AI applications for detecting MI through ECG data. Methods: A systematic search was performed in Ovid MEDLINE, Ovid Embase, Web of Science Core Collection, and Cochrane Central. The search covered publications from 2015 to 9 October 2024; non-English articles were included if a reliable translation was available. Studies that used AI to diagnose MI via ECG were eligible, and studies that used other diagnostic modalities were excluded. The review was performed per the PRISMA extension for scoping reviews (PRISMA-ScR) to ensure transparent and methodological reporting. Of a total of 7189 articles, 220 were selected for inclusion. Data extraction included parameters such as first author, year, country, AI model type, algorithm, ECG data type, accuracy, and AUC to ensure all relevant information was captured. Results: Publications began in 2015 with a peak in 2022. Most studies used 12-lead ECGs; the Physikalisch-Technische Bundesanstalt database and other public and single-center datasets were the most common sources. Convolutional neural networks and support vector machines predominated. While many reports described high apparent performance, these estimates frequently came from relatively small, single-source datasets and validation strategies prone to optimism. Cross-validation was reported in 57% of studies, whereas 36% did not specify their split method, and several noted that accuracy declined under inter-patient or external validation, indicating limited generalizability. Accordingly, headline figures (sometimes ≥99% for accuracy, sensitivity, or specificity) should be interpreted in light of dataset size, case mix, and validation design, with risks of spectrum/selection bias, overfitting, and potential data leakage when patient-level independence is not enforced. Conclusions: AI-based approaches for MI detection using ECGs have grown quickly. Diagnostic performance is limited by dataset and validation issues. Variability in reporting, datasets, and validation strategies have been noted, and standardization is needed. Future work should address clinical integration, explainability, and algorithmic fairness for safe and equitable deployment.

15 November 2022 in Cells
Verified
Journal Article
Open access
PDF file
Mohammad QneibiMohammad Qneibi
Mohammad Qneibi
SNSafa’ Nassar
Safa’ Nassar
Sosana BdirSosana Bdir
Sosana Bdir
AHAdel Hidmi
Adel Hidmi
The ionotropic glutamate receptor subtype α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) is responsible for most excitatory transmission in the brain. AMPA receptor function is altered in numerous neurological illnesses, making AMPA receptors appealing therapeutic targets for clinical intervention. Alpha-Lipoic acid (α-LA) is a naturally occurring compound, which functions as a co-factor in metabolism and energy production. α-LA is an antioxidant with various benefits in treating diabetes, including managing symptomatic diabetic neuropathy. This study will test a novel and innovative strategy to synthesize a new isomer of lipoic acid (R-LA) derivatives (bifunctional NO-donor/antioxidant) in one chemical on homomeric and heteromeric AMPA receptor subunits. We used patch-clamp electrophysiology to examine LA derivatives expressed in human embryonic kidney 293 cells (HEK293) for inhibition and changes in desensitization or deactivation rates. LA derivatives were shown to be potent antagonists of AMPA receptors, with an 8–11-fold reduction in AMPA receptor currents seen following the delivery of the compounds. Furthermore, the LA derivatives influenced the rates of desensitization and deactivation of AMPA receptors. Based on our results, especially given that α-LA is closely connected to the nervous system, we may better understand using AMPA receptors and innovative drugs to treat neurological diseases associated with excessive activation of AMPA receptors.

8 July 2024 in Molecules
Verified
Journal Article
Open access
Mohammad QneibiMohammad Qneibi
Mohammad Qneibi
MHmohammed hawash
mohammed hawash
Sosana BdirSosana Bdir
Sosana Bdir
Mohammad BdairMohammad Bdair
Mohammad Bdair
SASamia Ammar Aldwaik
Samia Ammar Aldwaik
An optimal balance between excitatory and inhibitory transmission in the central nervous system provides essential neurotransmission for good functioning of the neurons. In the neurology field, a disturbed balance can lead to neurological diseases like epilepsy, Alzheimer’s, and Autism. One of the critical agents mediating excitatory neurotransmission is α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors, which are concerned with synaptic plasticity, memory, and learning. An imbalance in neurotransmission finally results in excitotoxicity and neurological pathologies that should be corrected through specific compounds. Hence, the current study will prove to be an evaluation of new thiazole-carboxamide derivatives concerning AMPAR-modulating activity and extended medicinal potential. In the current project, five previously synthesized thiazole-carboxamide derivatives, i.e., TC-1 to TC-5, were used to interact with the AMPARs expressed in HEK293T cells, which overexpress different subunits of the AMPAR. Patch-clamp analysis was carried out while the effect of the drugs on AMPAR-mediated currents was followed with a particular emphasis on the kinetics of inhibition, desensitization, and deactivation. All tested TC compounds, at all subunits, showed potent inhibition of AMPAR-mediated currents, with TC-2 being the most powerful for all subunits. These compounds shifted the receptor kinetics efficiently, mainly enhancing the deactivation rates, and hence acted as a surrogate for their neuroprotective potentials. Additionally, recently published structure–activity relationship studies identified particular substituent groups as necessary for improving the pharmacologic profiles of these compounds. In this regard, thiazole-carboxamide derivatives, particularly those classified as TC-2, have become essential negative allosteric modulators of AMPAR function and potential therapeutics in neurological disturbances underlain by the dysregulation of excitatory neurotransmission. Given their therapeutic effectiveness and safety profiles, these in vivo studies need to be further validated, although computational modeling can be further developed for drug design and selectivity. This will open possibilities for new drug-like AMPAR negative allosteric modulators with applications at the clinical level toward neurology.